Please assess the completion status of the following clinical trial:

Trial Title: Study to Compare How the Body Distributes and Excretes the Drugs Jivi (BAY 94-9027) and Adynovi in Patients With Severe Hemophilia A (Bleeding Disorder Resulting From a Lack of Blood Clotting Factor VIII)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with severe hemophilia A (baseline FVIII activity FVIII:C \<1%), determined by measurement at the time of screening (following a washout period of at least 72 h after their last FVIII treatment for standard half-life FVIII products or of 120 h for extended half-life FVIII products) or from reliable prior documentation (e.g. measurement in other clinical studies, result from approved clinical laboratory or diagnostic genetic testing).~* ≥150 exposure days with FVIII concentrate(s) (plasma-derived or recombinant) as supported by medical records.~* Body mass index (BMI) within the range 18 kg/m2 to 29.9 kg/m2 (inclusive).~Exclusion Criteria:~* Inability to stop FVIII treatment to complete a minimum of 72 h washout for standard half-life FVIII product or 120 h washout for extended half-life FVIII product~* Evidence of current or past inhibitor antibody~* History of any congenital or acquired coagulation disorders other than hemophilia A~* Platelet count \<75,000/mm3~* Human immunodeficiency virus (HIV) infection with a cluster of differentiation 4 (CD4+) lymphocyte count of \<200/mm3~* Abnormal renal function (serum creatinine \>2x the upper limit of the normal range \[ULN\])~* Active liver disease verified by medical history or persistently elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>5x ULN or severe liver disease as evidenced by, but not limited to any of the following: International Normalized Ratio \>1.4, hypoalbuminemia, portal vein hypertension including presence of otherwise unexplained splenomegaly and history of esophageal varices~* Requirement of any pre-medication to tolerate FVIII treatment (e.g. anti-histamines)~* Prior treatment with immunomodulatory agents or chemotherapy within the last 3 months prior to study entry or requirement of treatment during the study. The following drugs are allowed: α interferon, PEG interferon, highly active anti-retroviral therapy for HIV, and/or a total of two courses of pulse treatment with steroid for a maximum of 7 days at 1 mg/kg or less

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- BAY94-9027 / Adynovi (Type: EXPERIMENTAL): Treatment sequence A-B with washout before each treatment
- Adynovi / BAY94-9027 (Type: EXPERIMENTAL): Treatment sequence B-A with washout before each treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).